Printer Friendly

Reportlinker Adds Osteoporosis Drugs: Technologies and Global Markets.

NEW YORK, Aug. 10 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Osteoporosis Drugs: Technologies and Global Markets

http://www.reportlinker.com/p0236234/Osteoporosis-Drugs-Technologies-and-Global-Markets.html

THIS REPORT CONTAINS:

* Discussion of osteoporosis drugs currently on the market in six major classes: biphosphonates, selective estrogen receptors modulators (SERMs), calcitonins, parathyroid hormones, dual-action bone agents, and hormone replacement therapies (HRTs)

* Analysis of market trends, with data for 2007 and 2008, estimates for 2009, and projections of compound annual growth rates (CAGRs) through 2014

* Breakdown of the industry structure for emerging drug classes

* Review of disease prevalence and region-specific aspects that affect the diagnosis and treatment of osteoporosis patients

* Comprehensive company profiles.

CHAPTER ONE: INTRODUCTION

STUDY GOALS AND OBJECTIVES

REASONS FOR DOING THE STUDY

SCOPE OF REPORT

METHODOLOGY

INTENDED AUDIENCE

INFORMATION SOURCES

ANALYST CREDENTIALS

RELATED BCC REPORTS

BCC ONLINE SERVICES

DISCLAIMER

CHAPTER TWO: SUMMARY

SUMMARY TABLE GLOBAL OSTEOPOROSIS DRUG MARKET BY

GEOGRAPHIC REGION, THROUGH 2014 ($ MILLIONS)

SUMMARY FIGURE GLOBAL OSTEOPOROSIS DRUG MARKET BY

GEOGRAPHIC REGION, 2007AyC2014 ($ MILLIONS)

CHAPTER THREE: OVERVIEW

INTRODUCTION

OSTEOPOROSIS OVERVIEW

MEDICATION TREATMENT

CLASSIFICATION OF OSTEOPOROSIS DRUGS

Bisphosphonates

SERMs

PTHs

Calcitonins

HRTs

TABLE 1 MARKETED OSTEOPOROSIS DRUGS

DRUG DELIVERY METHODS

Oral Drugs

Injectable Drugs

Nasal Spray and Transdermal Drugs

DRUG DEVELOPMENT PROCESS

INDUSTRY PLAYERS

MAJOR DRUG MANUFACTURERS

SPECIALTY PHARMACEUTICAL COMPANIES

SMALLER COMPANIES

COMPETITIVE FACTORS

SIGNIFICANT TRENDS

GLOBAL AGING POPULATION AND INCREASING LIFE EXPECTANCY TO LEAD TO THE RISING PREVALENCE OF OSTEOPOROSIS

LAUNCH OF NOVEL MECHANISM DRUGS AND IMPROVED FORMULATIONS OF MARKETED DRUGS TO ENHANCE TREATMENT OPTIONS

PATENT EXPIRATIONS OF BLOCKBUSTER DRUGS AND GENERIC DRUG LAUNCHES TO HINDER MARKET GROWTH

CHAPTER FOUR: DISEASE OVERVIEW

OSTEOPOROSIS OVERVIEW

OVERVIEW OF THE BONE

BONE STRUCTURE

BONE REMODELING

THE ROLES OF HORMONES IN BONE HEALTH

The Roles of Hormones AAi- (Continued)

CLASSIFICATION OF OSTEOPOROSIS

WHO CLASSIFICATION

TABLE 2 WHO CLASSIFICATION OF OSTEOPOROSIS

PRIMARY VERSUS SECONDARY OSTEOPOROSIS

MAYO CLINIC CLASSIFICATION

TABLE 3 MAYO CLINIC CLASSIFICATION OF OSTEOPOROSIS

OSTEOPOROSIS CAUSES AND RISK FACTORS

DIAGNOSIS

OSTEOPOROSIS COMPLICATIONS

DRUG CLASSES APPROVED IN THE TREATMENT OF OSTEOPOROSIS

TABLE 4 OSTEOPOROSIS DRUG CLASSES

BISPHOSPHONATES

SERMS

PTHS

DABAS

CALCITONINS

HRTS

TABLE 5 OSTEOPOROSIS DRUG CLASSES COMPARISON

MEDICATION TREATMENT ALGORITHMS

FIRST LINE OF THERAPY

SECOND LINE OF THERAPY

THIRD LINE OF THERAPY

CHAPTER FIVE: PATIENT POPULATION ANALYSIS

OVERVIEW

TABLE 6 OSTEOPOROSIS-RELATED FRACTURES BY PATIENTS' GENDER, 2006 (%)

PATIENT POPULATION CHARACTERISTICS: U.S. AND CANADA

TABLE 7 ESTIMATED OSTEOPOROSIS PATIENT POPULATION: U.S. AND CANADA, 2010 (MILLIONS)

U.S

TABLE 8 PREVALENCE OF OSTEOPOROSIS IN THE U.S., AGE >/= 65 YEARS, 2004 (%)

TABLE 9 U.S. OSTEOPOROSIS-RELATED FRACTURES, 2005

CANADA

PATIENT POPULATION CHARACTERISTICS: EU

TABLE 10 ESTIMATED OSTEOPOROSIS PATIENT POPULATION IN THE EU, 2009 (MILLIONS)

GERMANY

FRANCE

ITALY

SPAIN

U.K.

TABLE 11 U.K. OSTEOPOROSIS-RELATED FRACTURES, 2005

TABLE 12 NUMBER OF HIP FRACTURES PER YEAR IN EU COUNTRIES, 2005

PATIENT POPULATION CHARACTERISTICS: ROW

TABLE 13 ESTIMATED OSTEOPOROSIS PATIENT POPULATION: SELECTED COUNTRIES IN THE ROW, 2009 (MILLIONS)

CHINA

INDIA

JAPAN

LATIN AMERICA

CHAPTER SIX: INDUSTRY STRUCTURE AND COMPETITIVE ANALYSIS

INDUSTRY STRUCTURE

TIERS OF COMPETITION

TABLE 14 INDUSTRY STRUCTURE: MAJOR COMPETITORS AND MARKETED PRODUCTS

MARKET CONCENTRATION AND PRICE SENSITIVITY

BARRIERS TO ENTRY

Market Saturation and Competitiveness

Sales and Marketing Capabilities

Scientific and Regulatory Challenges in the Development of New Drugs

NOTABLE MERGERS AND ACQUISITIONS

COMPETITIVE FACTORS

PRICE

PRODUCT EFFICACY AND DOSAGE FREQUENCY

DRUG DELIVERY MODE AND CONVENIENCE

SAFETY PROFILE

MARKETING AND SALES EFFECTIVENESS

MARKET CHALLENGES

DISEASE UNDERDIAGNOSIS AND UNDERTREATMENT

POOR PATIENT ADHERENCE TO MEDICATION THERAPY

DRUG REIMBURSEMENT ISSUES

INCREASED SCRUTINY IN THE APPROVAL OF NEW DRUGS

UNMET MARKET NEEDS

IMPROVED ANABOLIC DRUGS

DRUGS WITH SUPERIOR EFFICACY

IMPROVED SIDE EFFECTS AND SAFETY PROFILE DRUGS

IMPROVED DRUG DELIVERY MODALITIES

IMPROVED IDENTIFICATION OF PATIENTS REQUIRING THERAPY

MARKET TRENDS

TABLE 15 MARKET TRENDS IN THE OSTEOPOROSIS MEDICATION MARKET

INCREASED PREVALENCE OF OSTEOPOROSIS AND LIFE EXPECTANCY ARE EXPECTED TO DRIVE MARKET GROWTH GLOBALLY

ENHANCED PATIENT AND PHYSICIAN AWARENESS IS EXPECTED TO LEAD TO EARLIER DISEASE DIAGNOSIS AND TREATMENT

NEW PRODUCT LAUNCHES WITH ENHANCED EFFICACY, CONVENIENCE, AND SAFETY PROFILES ARE EXPECTED TO EXPAND THE MARKET

COST CONSTRAINTS TO AFFECT DRUG CHOICE AND REVENUES

LOSS OF PATENT PROTECTION FOR MAJOR BLOCKBUSTER DRUGS TO SLOW OVERALL MARKET GROWTH

TOTAL MARKET REVENUES AND FORECAST

TOTAL MARKET REVENUES

TABLE 16 GLOBAL OSTEOPOROSIS DRUG MARKET BY DRUG CLASS, 2008 ($ MILLIONS)

FIGURE 1 GLOBAL OSTEOPOROSIS DRUG MARKET BY DRUG CLASS, 2008 (%)

MARKET SHARES

TABLE 17 GLOBAL OSTEOPOROSIS DRUG MARKET SHARES BY COMPANY AND PRODUCT, 2008 (%)

FIGURE 2 GLOBAL OSTEOPOROSIS DRUG MARKET SHARES BY COMPANY AND PRODUCT, 2008 (%)

MARKET FORECAST

TABLE 18 GLOBAL OSTEOPOROSIS DRUG MARKET BY GEOGRAPHIC REGION, THROUGH 2014 ($ MILLIONS)

FIGURE 3 GLOBAL OSTEOPOROSIS DRUG MARKET BY GEOGRAPHIC REGION, 2007AyC2014 ($ MILLIONS)

Forecast Assumptions

Existing Drug Revenues

Patent Expirations of Major Drugs

Expected New Drug Launches

CHAPTER SEVEN: MARKETS BY DRUG CLASSES

BISPHOSPHONATES

OVERVIEW

TABLE 19 BISPHOSPHONATES INDUSTRY STRUCTURE, 2009

COMPETITIVE ASPECTS

SAFETY CONCERNS

MARKET REVENUES AND FORECAST

TABLE 20 GLOBAL BISPHOSPHONATES MARKET SHARES BY COMPANY, 2008 (%)

FIGURE 4 GLOBAL BISPHOSPHONATES MARKET SHARES BY COMPANY AND PRODUCT, 2008 (%)

TABLE 21 GLOBAL BISPHOSPHONATES MARKET BY DRUG CLASS, THROUGH 2014 ($ MILLIONS)

FIGURE 5 GLOBAL BISPHOSPHONATES MARKET BY DRUG CLASS, 2007AyC2014 ($ MILLIONS)

PRODUCT ANALYSIS

Fosamax

Competitive Aspects

TABLE 22 FOSAMAX ANALYSIS

Actonel

Competitive Aspects

TABLE 23 ACTONEL ANALYSIS

Boniva/Bonviva

Competitive Aspects

TABLE 24 BONIVA/BONVIVA ANALYSIS

Reclast/Aclasta

Competitive Aspects

TABLE 25 RECLAST/ACLASTA ANALYSIS

SERMS

OVERVIEW

TABLE 26 SERM INDUSTRY STRUCTURE, 2009

COMPETITIVE ASPECTS

MARKET REVENUES AND FORECAST

TABLE 27 GLOBAL SERM MARKET SHARES BY COMPANY AND PRODUCT, 2008 (%)

FIGURE 6 GLOBAL SERM MARKET SHARES BY COMPANY AND PRODUCT, 2008 (%)

TABLE 28 GLOBAL SERM MARKET REVENUES, THROUGH 2014 ($ MILLIONS)

FIGURE 7 GLOBAL SERM MARKET REVENUES, 2007AyC2014 ($ MILLIONS)

PRODUCTS ANALYSIS

Evista

Competitive Aspects

TABLE 29 EVISTA ANALYSIS

PTHS

OVERVIEW

TABLE 30 PTH DRUG INDUSTRY STRUCTURE, 2009

COMPETITIVE ASPECTS

MARKET REVENUES AND FORECAST

TABLE 31 GLOBAL PTH MARKET SHARES BY COMPANY AND PRODUCT, 2008 (%)

FIGURE 8 GLOBAL PTH MARKET SHARES BY COMPANY AND PRODUCT, 2008 (%)

TABLE 32 GLOBAL PTH MARKET REVENUES, THROUGH 2014 ($ MILLIONS)

FIGURE 9 GLOBAL PTH MARKET REVENUES, 2007AyC2014 ($ MILLIONS)

PRODUCT ANALYSIS

Forteo/Forsteo

Competitive Aspects

TABLE 33 FORTEO ANALYSIS

CALCITONINS

OVERVIEW

TABLE 34 CALCITONINS INDUSTRY STRUCTURE, 2009

COMPETITIVE ASPECTS

MARKET REVENUES AND FORECAST

TABLE 35 GLOBAL CALCITONINS MARKET SHARES BY COMPANY AND PRODUCT, 2008 (%)

FIGURE 10 GLOBAL CALCITONINS MARKET SHARES BY COMPANY AND PRODUCT, 2008 (%)

TABLE 36 GLOBAL CALCITONINS MARKET, THROUGH 2014 ($ MILLIONS)

FIGURE 11 GLOBAL CALCITONINS MARKET, 2007AyC2014 ($ MILLIONS)

PRODUCT ANALYSIS

Miacalcin/Miacalcic

Competitive Aspects

TABLE 37 MIACALCIN ANALYSIS

DABAS

OVERVIEW

TABLE 38 DABA INDUSTRY STRUCTURE, 2009

COMPETITIVE ASPECTS

MARKET REVENUES AND FORECAST

TABLE 39 GLOBAL DABA MARKET REVENUES, THROUGH 2014 ($ MILLIONS)

FIGURE 12 GLOBAL DABAS MARKET REVENUES, 2007AyC2014 ($ MILLIONS)

PRODUCT ANALYSIS

Protelos

Competitive Aspects

TABLE 40 PROTELOS ANALYSIS

HRT

OVERVIEW

TABLE 41 SELECTED MARKETED HRT DRUGS, 2009

COMPETITIVE ASPECTS

MARKET REVENUES AND FORECAST

TABLE 42 GLOBAL HRT MARKET SHARES BY COMPANY AND PRODUCT, 2008 (%)

FIGURE 13 GLOBAL HRT MARKET SHARES BY COMPANY AND PRODUCT, 2008 (%)

TABLE 43 GLOBAL HRT MARKET, THROUGH 2014 ($ MILLIONS)

FIGURE 14 GLOBAL HRT MARKET, 2007AyC2014 ($ MILLIONS)

PRODUCTS ANALYSIS

Premarin Line of Products

Competitive Aspects

TABLE 44 PREMARIN PRODUCTS LINE ANALYSIS

EMERGING DRUG CLASSES

OVERVIEW

TABLE 45 EMERGING DRUG CLASSES

PRODUCT ANALYSIS

Prolia

TABLE 46 PROLIA PROFILE

Odanacatib

TABLE 47 ODANACATIB PROFILE

EMERGING DRUG CLASSES FORECAST

TABLE 48 GLOBAL MARKET REVENUES FOR NEW MECHANISM DRUGS, THROUGH 2014 ($ MILLIONS)

FIGURE 15 GLOBAL MARKET REVENUES FOR NEW MECHANISM DRUGS, 2007AyC2014 ($ MILLIONS)

CHAPTER EIGHT: MARKETS BY GEOGRAPHICAL REGIONS

U.S.

MARKET OVERVIEW: PRODUCTS, SIGNIFICANT ASPECTS

Market Overview

TABLE 49 U.S. MARKET SHARES OF OSTEOPOROSIS PRESCRIPTION DRUGS BY COMPANY AND PRODUCT, 2008 (%)

FIGURE 16 U.S. MARKET SHARES OF OSTEOPOROSIS PRESCRIPTION DRUGS BY COMPANY AND PRODUCT, 2008 (%)

Products

Significant Aspects

REVENUE FORECAST

TABLE 50 U.S. MARKET FOR OSTEOPOROSIS PRESCRIPTION DRUGS, THROUGH 2014 ($ MILLIONS)

FIGURE 17 U.S. MARKET FOR OSTEOPOROSIS PRESCRIPTION DRUGS, 2007AyC2014 ($ MILLIONS)

EU

MARKET OVERVIEW: PRODUCTS, SIGNIFICANT ASPECTS

Market Overview

TABLE 51 EU MARKET SHARES OF OSTEOPOROSIS PRESCRIPTION DRUGS BY COMPANY AND PRODUCT, 2008 (%)

FIGURE 18 EU MARKET SHARES OF OSTEOPOROSIS PRESCRIPTION DRUGS BY COMPANY AND PRODUCT, 2008 (%)

Products

Significant Aspects

REVENUE FORECAST

TABLE 52 EU OSTEOPOROSIS PRESCRIPTION DRUG MARKET, THROUGH 2014 ($ MILLIONS)

FIGURE 19 EU OSTEOPOROSIS PRESCRIPTION DRUG MARKET, 2007AyC2014 ($ MILLIONS)

ROW MARKET

MARKET OVERVIEW: PRODUCTS, SIGNIFICANT ASPECTS

Market Overview

TABLE 53 ROW MARKET SHARES OF OSTEOPOROSIS PRESCRIPTION DRUGS BY COMPANY AND PRODUCT, 2008 (%)

FIGURE 20 ROW MARKET SHARES OF OSTEOPOROSIS PRESCRIPTION DRUGS BY COMPANY AND PRODUCT, 2008 (%)

Products

Significant Aspects

REVENUE FORECAST

TABLE 54 ROW OSTEOPOROSIS PRESCRIPTION DRUG MARKET, THROUGH 2014 ($ MILLIONS)

FIGURE 21 ROW OSTEOPOROSIS PRESCRIPTION DRUG MARKET, 2007AyC2014 ($ MILLIONS)

CHAPTER NINE: PIPELINE REVIEW

PIPELINE OVERVIEW

RANK-LIGAND INHIBITORS

CATHEPSIN K INHIBITORS

SCLEROSTIN INHIBITORS

CALCILYTICS

DKK-1 ANTAGONISTS

DRUGS FILED FOR REGULATORY APPROVAL

PROLIA (DENOSUMAB)

CONBRIZA/VIVIANT (BAZEDOXIFENE)

FABLYN/OPORIA (LASOFOXIFENE)

TABLE 55 OSTEOPOROSIS PIPELINE: DRUGS FILED FOR REGULATORY APPROVAL, 2010

DRUGS IN PHASE III CLINICAL TRIALS

BISPHOSPHONATES

CALCITONINS

CATHEPSIN K INHIBITORS

SERMS/HRTS

PTHS

TABLE 56 GLOBAL PHASE III OSTEOPOROSIS PIPELINE, 2010

DRUGS IN PHASE II CLINICAL TRIALS

BISPHOSPHONATES

BONE MORPHOGENETIC PROTEIN

CALCILYTICS

CALCITONINS

CATHEPSIN K INHIBITORS

DABAS

PTHS

SCLEROSTIN INHIBITORS

TABLE 57 GLOBAL PHASE II OSTEOPOROSIS PIPELINE, 2010

DRUGS IN PHASE I CLINICAL TRIALS

DKK-1 ANTAGONISTS

PTHS

RANK-LIGAND INHIBITORS

SCLEROSTIN INHIBITORS

SRC KINASE INHIBITORS

TABLE 58 GLOBAL PHASE I OSTEOPOROSIS PIPELINE, 2010

CHAPTER TEN: COMPANY PROFILES

ABLYNX NV

AEGIS THERAPEUTICS, LLC

AMGEN, INC.

BONE MEDICAL, LTD.

CHUGAI PHARMACEUTICAL

DAIICHI SANKYO

EFFRX, INC.

ELI LILLY

EMISPHERE TECHNOLOGIES

GLAXO WELLCOME U.K., LTD.

GLAXOSMITHKLINE U.S.

GREEN CROSS CORP.

LES LABORATOIRES SERVIER

MERCK & CO., INC.

MERRION PHARMACEUTICALS

NOVARTIS PHARMA

NOVARTIS CORP.

NOVARTIS PHARMACEUTICALS CORP.

NOVO NORDISK

NPS PHARMACEUTICALS

NYCOMED INTERNATIONAL MANAGEMENT GMBH

OSTEOLOGIX

PFIZER, INC.

PROXIMA CONCEPTS

RADIUS HEALTH

RANBAXY LABORATORIES

ROCHE

HOFFMANN- LA ROCHE PHARMACEUTICALS

SANOFI-AVENTIS

SANOFI-AVENTIS U.S.

TAISHO PHARMACEUTICAL

TEIJIN PHARMA, LTD.

TEIJIN AMERICA, INC.

TEVA PHARMACEUTICAL INDUSTRIES, LTD.

TEVA PHARMACEUTICALS USA

TRANSPHARMA MEDICAL, LTD.

UNIGENE LABORATORIES

WARNER CHILCOTT, PLC

ZELOS THERAPEUTICS, INC.

ZOSANO PHARMA

CHAPTER ELEVEN: NASCENT PATENT APPLICATION ACTIVITY

NASCENT PATENT APPLICATION ACTIVITY

LIST OF TABLES

SUMMARY TABLE GLOBAL OSTEOPOROSIS DRUG MARKET BY

GEOGRAPHIC REGION, THROUGH 2014 ($ MILLIONS)

TABLE 1 MARKETED OSTEOPOROSIS DRUGS

TABLE 2 WHO CLASSIFICATION OF OSTEOPOROSIS

TABLE 3 MAYO CLINIC CLASSIFICATION OF OSTEOPOROSIS

TABLE 4 OSTEOPOROSIS DRUG CLASSES

TABLE 5 OSTEOPOROSIS DRUG CLASSES COMPARISON

TABLE 6 OSTEOPOROSIS-RELATED FRACTURES BY PATIENTS'

GENDER, 2006 (%)

TABLE 7 ESTIMATED OSTEOPOROSIS PATIENT POPULATION: U.S.

AND CANADA, 2010 (MILLIONS)

TABLE 8 PREVALENCE OF OSTEOPOROSIS IN THE U.S., AGE >/= 65

YEARS, 2004 (%)

TABLE 9 U.S. OSTEOPOROSIS-RELATED FRACTURES, 2005

TABLE 10 ESTIMATED OSTEOPOROSIS PATIENT POPULATION IN

THE EU, 2009 (MILLIONS)

TABLE 11 U.K. OSTEOPOROSIS-RELATED FRACTURES, 2005

TABLE 12 NUMBER OF HIP FRACTURES PER YEAR IN EU

COUNTRIES, 2005

TABLE 13 ESTIMATED OSTEOPOROSIS PATIENT POPULATION:

SELECTED COUNTRIES IN THE ROW, 2009 (MILLIONS)

TABLE 14 INDUSTRY STRUCTURE: MAJOR COMPETITORS AND

MARKETED PRODUCTS

TABLE 15 MARKET TRENDS IN THE OSTEOPOROSIS MEDICATION

MARKET

TABLE 16 GLOBAL OSTEOPOROSIS DRUG MARKET BY DRUG CLASS,

2008 ($ MILLIONS)

TABLE 17 GLOBAL OSTEOPOROSIS DRUG MARKET SHARES BY

COMPANY AND PRODUCT, 2008 (%)

TABLE 18 GLOBAL OSTEOPOROSIS DRUG MARKET BY GEOGRAPHIC

REGION, THROUGH 2014 ($ MILLIONS)

TABLE 19 BISPHOSPHONATES INDUSTRY STRUCTURE, 2009

TABLE 20 GLOBAL BISPHOSPHONATES MARKET SHARES BY

COMPANY, 2008 (%)

TABLE 21 GLOBAL BISPHOSPHONATES MARKET BY DRUG CLASS,

THROUGH 2014 ($ MILLIONS)

TABLE 22 FOSAMAX ANALYSIS

TABLE 23 ACTONEL ANALYSIS

TABLE 24 BONIVA/BONVIVA ANALYSIS

TABLE 25 RECLAST/ACLASTA ANALYSIS

TABLE 26 SERM INDUSTRY STRUCTURE, 2009

TABLE 27 GLOBAL SERM MARKET SHARES BY COMPANY AND

PRODUCT, 2008 (%)

TABLE 28 GLOBAL SERM MARKET REVENUES, THROUGH 2014 ($

MILLIONS)

TABLE 29 EVISTA ANALYSIS

TABLE 30 PTH DRUG INDUSTRY STRUCTURE, 2009

TABLE 31 GLOBAL PTH MARKET SHARES BY COMPANY AND

PRODUCT, 2008 (%)

TABLE 32 GLOBAL PTH MARKET REVENUES, THROUGH 2014 ($

MILLIONS)

TABLE 33 FORTEO ANALYSIS

TABLE 34 CALCITONINS INDUSTRY STRUCTURE, 2009

TABLE 35 GLOBAL CALCITONINS MARKET SHARES BY COMPANY

AND PRODUCT, 2008 (%)

TABLE 36 GLOBAL CALCITONINS MARKET, THROUGH 2014 ($

MILLIONS)

TABLE 37 MIACALCIN ANALYSIS

TABLE 38 DABA INDUSTRY STRUCTURE, 2009

TABLE 39 GLOBAL DABA MARKET REVENUES, THROUGH 2014 ($

MILLIONS)

TABLE 40 PROTELOS ANALYSIS

TABLE 41 SELECTED MARKETED HRT DRUGS, 2009

TABLE 42 GLOBAL HRT MARKET SHARES BY COMPANY AND

PRODUCT, 2008 (%)

TABLE 43 GLOBAL HRT MARKET, THROUGH 2014 ($ MILLIONS)

TABLE 44 PREMARIN PRODUCTS LINE ANALYSIS

TABLE 45 EMERGING DRUG CLASSES

TABLE 46 PROLIA PROFILE

TABLE 47 ODANACATIB PROFILE

TABLE 48 GLOBAL MARKET REVENUES FOR NEW MECHANISM

DRUGS, THROUGH 2014 ($ MILLIONS)

TABLE 49 U.S. MARKET SHARES OF OSTEOPOROSIS PRESCRIPTION

DRUGS BY COMPANY AND PRODUCT, 2008 (%)

TABLE 50 U.S. MARKET FOR OSTEOPOROSIS PRESCRIPTION DRUGS,

THROUGH 2014 ($ MILLIONS)

TABLE 51 EU MARKET SHARES OF OSTEOPOROSIS PRESCRIPTION

DRUGS BY COMPANY AND PRODUCT, 2008 (%)

TABLE 52 EU OSTEOPOROSIS PRESCRIPTION DRUG MARKET,

THROUGH 2014 ($ MILLIONS)

TABLE 53 ROW MARKET SHARES OF OSTEOPOROSIS PRESCRIPTION

DRUGS BY COMPANY AND PRODUCT, 2008 (%)

TABLE 54 ROW OSTEOPOROSIS PRESCRIPTION DRUG MARKET,

THROUGH 2014 ($ MILLIONS)

TABLE 55 OSTEOPOROSIS PIPELINE: DRUGS FILED FOR

REGULATORY APPROVAL, 2010

TABLE 56 GLOBAL PHASE III OSTEOPOROSIS PIPELINE, 2010

TABLE 57 GLOBAL PHASE II OSTEOPOROSIS PIPELINE, 2010

TABLE 58 GLOBAL PHASE I OSTEOPOROSIS PIPELINE, 2010

SUMMARY FIGURE GLOBAL OSTEOPOROSIS DRUG MARKET BY

GEOGRAPHIC REGION, 2007AyC2014 ($ MILLIONS)

FIGURE 1 GLOBAL OSTEOPOROSIS DRUG MARKET BY DRUG CLASS,

2008 (%)

FIGURE 2 GLOBAL OSTEOPOROSIS DRUG MARKET SHARES BY

COMPANY AND PRODUCT, 2008 (%)

FIGURE 3 GLOBAL OSTEOPOROSIS DRUG MARKET BY GEOGRAPHIC

REGION, 2007AyC2014 ($ MILLIONS)

FIGURE 4 GLOBAL BISPHOSPHONATES MARKET SHARES BY

COMPANY AND PRODUCT, 2008 (%)

FIGURE 5 GLOBAL BISPHOSPHONATES MARKET BY DRUG CLASS,

2007AyC2014 ($ MILLIONS)

FIGURE 6 GLOBAL SERM MARKET SHARES BY COMPANY AND

PRODUCT, 2008 (%)

FIGURE 7 GLOBAL SERM MARKET REVENUES, 2007AyC2014 ($

MILLIONS)

FIGURE 8 GLOBAL PTH MARKET SHARES BY COMPANY AND

PRODUCT, 2008 (%)

FIGURE 9 GLOBAL PTH MARKET REVENUES, 2007AyC2014 ($ MILLIONS) .... 106

FIGURE 10 GLOBAL CALCITONINS MARKET SHARES BY COMPANY

AND PRODUCT, 2008 (%)

FIGURE 11 GLOBAL CALCITONINS MARKET, 2007AyC2014 ($ MILLIONS)

FIGURE 12 GLOBAL DABAS MARKET REVENUES, 2007AyC2014 ($

MILLIONS)

FIGURE 13 GLOBAL HRT MARKET SHARES BY COMPANY AND

PRODUCT, 2008 (%)

FIGURE 14 GLOBAL HRT MARKET, 2007AyC2014 ($ MILLIONS)

FIGURE 15 GLOBAL MARKET REVENUES FOR NEW MECHANISM

DRUGS, 2007AyC2014 ($ MILLIONS)

FIGURE 16 U.S. MARKET SHARES OF OSTEOPOROSIS PRESCRIPTION

DRUGS BY COMPANY AND PRODUCT, 2008 (%)

FIGURE 17 U.S. MARKET FOR OSTEOPOROSIS PRESCRIPTION

DRUGS, 2007AyC2014 ($ MILLIONS)

FIGURE 18 EU MARKET SHARES OF OSTEOPOROSIS PRESCRIPTION

DRUGS BY COMPANY AND PRODUCT, 2008 (%)

FIGURE 19 EU OSTEOPOROSIS PRESCRIPTION DRUG MARKET,

2007AyC2014 ($ MILLIONS)

FIGURE 20 ROW MARKET SHARES OF OSTEOPOROSIS

PRESCRIPTION DRUGS BY COMPANY AND PRODUCT, 2008 (%)

FIGURE 21 ROW OSTEOPOROSIS PRESCRIPTION DRUG MARKET,

2007AyC2014 ($ MILLIONS)

To order this report:

Drug and Medication Industry: Osteoporosis Drugs: Technologies and Global Markets

Drug and Medication Business News

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!


Nicolas Bombourg


Reportlinker


Email: nbo@reportlinker.com


US: (805)-652-2626


Intl: +1 805-652-2626


SOURCE Reportlinker
COPYRIGHT 2010 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 10, 2010
Words:3698
Previous Article:Former Wilderness EMT Enjoys New Career as Professional Massage Therapist.
Next Article:Reportlinker Adds Global Markets for Ophthalmic Devices, Diagnostics and Surgical Equipment.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters